ROSZET
Peakezetimibe; rosuvastatin calcium
NDAORALTABLET
Approved
Mar 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
ROSZET (ezetimibe; rosuvastatin calcium) is intestine. First approved in 2021.
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ROSZET is a fixed-dose combination tablet containing ezetimibe and rosuvastatin calcium, approved in March 2021 for cholesterol management. Ezetimibe inhibits the Niemann-Pick C1-Like 1 (NPC1L1) sterol transporter at the intestinal brush border to block cholesterol absorption, while rosuvastatin reduces hepatic cholesterol synthesis via HMG-CoA reductase inhibition. The dual mechanism delivers complementary LDL-lowering effects through distinct pathways.
Peak7.0 years to LOE
Product is at peak commercialization stage with mature market positioning; commercial teams are focused on market share defense and clinical evidence building rather than launch activities.
Mechanism of Action
intestine. The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols. Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ROSZET offers stable, mature-stage pharma career opportunities in commercial and medical affairs functions, with limited research and development roles. Professionals joining this brand should expect focus on market defense, compliance, and field execution rather than innovation or launch activities.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.